Jill Marie Broadfoot - Jan 8, 2025 Form 4 Insider Report for aTYR PHARMA INC (ATYR)

Role
Chief Financial Officer
Signature
/s/ Nancy E. Denyes, attorney-in-fact
Stock symbol
ATYR
Transactions as of
Jan 8, 2025
Transactions value $
$0
Form type
4
Date filed
1/10/2025, 04:05 PM
Previous filing
Jun 24, 2024
Next filing
Feb 4, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATYR Employee Stock Option (right to buy) Award $0 +275K $0.00 275K Jan 8, 2025 Common Stock 275K $3.74 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning February 8, 2025, such that this option will be fully exercisable on January 8, 2029. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.